Savara

SVRA · NASDAQ

$4.76+$0.13 (+2.81%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $4.63

SVRA analyst rating

BuyConsensus of 5 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy5
Hold0
Underperform0
Sell0

12-month price target · 10 analysts

Average $11.16 (+134.4% upside)

Low: $9.09
Now: $4.76
High: $16.80

Upgrades and downgrades

The latest rating actions, newest first

SVRA analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
JP Morgan	Oct 7, 2026	Initiates	Overweight	$12.00	0%
HC Wainwright & Co.	Dec 23, 2025	Maintains	Buy	$8.00 → $10.00	54%
Wells Fargo	Dec 18, 2025	Maintains	Overweight	$7.00 → $9.00	29%
Oppenheimer	Nov 14, 2025	Maintains	Outperform	$8.00 → $9.00	45%
Citizens	Nov 13, 2025	Maintains	Market Outperform	$11.00 → $10.00	47%
JMP Securities	Oct 23, 2025	Maintains	Market Outperform	$8.00 → $11.00	47%

The case for and against

Updated May 5, 2026

Bull case

Savara is in an advantageous position with a clear regulatory path for Molbreevi's approval, positive interactions with the FDA, and a successful resubmission of the BLA with Fujifilm Diosynth Biotechnologies as the drug substance manufacturer, highlighting a strong CMC package. The increase in confirmed aPAP patients to ~5,500 and a larger, better-defined patient population, coupled with Molbreevi's broad efficacy and DLCO% as a clinically-meaningful endpoint, contribute to a favorable outlook for Savara. Additionally, with a recent $149.5 million equity financing and a $75 million royalty funding agreement, Savara has ample financial resources to support the launch of Molbreevi.

Bear case

Savara is facing several challenges, including a weak market potential with only one product candidate in Phase 3 development, limited market competition, and uncertain approval timeline, projected for August 2026. Despite the potential $1B opportunity for MOLBREEVI in aPAP, the company has yet to secure approval, and recent claims data show only a limited pool of potential patients, leading to a negative outlook on Savara's financial prospects. The company's stock may continue to struggle in the short term due to these factors.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.